89BIO INC. - COMMON S

89bio to Participate in Upcoming Investor Conferences

29 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Appoints Francis Sarena as Chief Operating Officer

07 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

05 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

05 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

22 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

14 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio to Participate in the BofA Securities 2024 Health Care Conference

08 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

02 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

17 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

27 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

12 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio to Participate in the Leerink Partners Global Biopharma Conference

05 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

29 2 2024 16:05:00 提供 Nasdaq GlobeNewswire